Bright Minds Biosciences Inc. (NASDAQ:DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). • Bright Minds Biosciences stock is showing exceptional strength. What’s driving DRUG stock higher?DEE is a severe group of brain disorders where frequent, often drug-resistant seizures significantly worsen developmental progress, causing delays or loss ...